Figure 2. Adjusted Associations Between P2Y₁₂ Inhibitor Copayment Reduction Intervention and Persistence and Adherence to Secondary Prevention Medications.

Patients in the intervention arm had higher rates of persistence and adherence to non–P2Y₁₂ inhibitor secondary prevention medications than the usual-care arm in both the intent-to-treat and as-treated arms. Results for the intent-to-treat population (A) and with patients who did not use vouchers excluded (B); the outcome of the intervention was greater when those who did not use vouchers were excluded. Variables for adjustment included hospital characteristics, demographic information, comorbidities, details of the index presentation and hospital course, and patient responses to baseline survey questions about quality of life and medication-taking behaviors. ACE indicates antiotengin-converting enzyme; ARB, angiotension II–receptor blocker.